Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
Authors Babiker HM, Riaz IB, Husnain M, Borad MJ
Received 27 November 2018
Accepted for publication 27 November 2018
Published 4 January 2019 Volume 2019:8 Pages 1—2
Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic Virother. 2017;6:11–18.
On page 16, left column, line 19 from the bottom, our publication indicates: “However, the data should be interpreted with caution, given the retrospective nature of the study, lack of control arm or randomization and other biases inherent with studies that are not prospective in nature”. However, the trial did have 52 malignant melanoma patients (post-surgical resection stages IB, IIA, IIB, and IIC) who did receive Rigvir, and 27 patients who were observed and treated per the standard guidelines (control group). Hence, there was a control group as in indicated in Figure 1 in the Doniņa et al paper.1
On page 16, left column, line 16 from the bottom, our publication indicates: “From a safety perspective, it was reported that there were no severe treatment-related toxicities. However, detailed data supporting this were not provided in the study publication, making it difficult to interpret objectively”. The authors would like to indicate regarding publication by Doniņa et al,1 Melanoma Research 2015, that Table 4 detailed the serum chemistry parameters of the patients. While no details of clinical adverse events, serious adverse events, or treatment related adverse events were highlighted, the authors do indicate on the paper that “In this retrospective study, however, that there was no record of any untoward side effect from Rigvir treatment or its discontinuation” (page 423 line 7 from the bottom,Doniņa et al1).
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]